These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8520342)

  • 21. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.
    Friedel HA; Langtry HD; Buckley MM
    Drugs; 1993 Jan; 45(1):131-56. PubMed ID: 7680981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse effect of drug-induced emotional problems on work and daily activities. A principal component as an independent predictor of ADRs in Shanghai patients with osteo-arthropathy taking nabumetone.
    Shi W; Wang YM; Li SL; Yan M
    Int J Clin Pharmacol Ther; 2004 Jun; 42(6):321-7. PubMed ID: 15222724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone.
    Wyplosz B; Vautier S; Lillo-Le Louët A; Capron L
    Br J Clin Pharmacol; 2006 Apr; 61(4):474. PubMed ID: 16542210
    [No Abstract]   [Full Text] [Related]  

  • 24. Nabumetone--a new NSAID.
    Med Lett Drugs Ther; 1992 Apr; 34(868):38-40. PubMed ID: 1556995
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of nabumetone in 4,541 elderly patients from a drug monitoring study.
    Münzel P; Lemmel EE
    Drugs; 1990; 40 Suppl 5():62-4. PubMed ID: 2081496
    [No Abstract]   [Full Text] [Related]  

  • 26. NSAIDs for the new decade--nabumetone?
    Huskisson EC
    Eur J Rheumatol Inflamm; 1991; 11(3):1-2. PubMed ID: 1365475
    [No Abstract]   [Full Text] [Related]  

  • 27. Low direct cytotoxicity of nabumetone on gastric mucosal cells.
    Arai Y; Tanaka K; Ushijima H; Tomisato W; Tsutsumi S; Aburaya M; Hoshino T; Yokomizo K; Suzuki K; Katsu T; Tsuchiya T; Mizushima T
    Dig Dis Sci; 2005 Sep; 50(9):1641-6. PubMed ID: 16133963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic implications associated with renal studies of nabumetone.
    Aronoff GR
    J Rheumatol Suppl; 1992 Nov; 36():25-31. PubMed ID: 1474532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of Italian clinical trials of nabumetone.
    Vaiani G; Grossi E
    Drugs; 1990; 40 Suppl 5():48-9. PubMed ID: 2150505
    [No Abstract]   [Full Text] [Related]  

  • 30. [Nabumetone is an alternative].
    Melander A
    Lakartidningen; 2003 Apr; 100(17):1547. PubMed ID: 12756699
    [No Abstract]   [Full Text] [Related]  

  • 31. When is an indole not an indole?
    Martin JA; Brownbill K
    Clin Chem; 1998 Jan; 44(1):186. PubMed ID: 9550580
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
    Ashworth NL; Peloso PM; Muhajarine N; Stang M
    J Rheumatol; 2005 Nov; 32(11):2212-7. PubMed ID: 16265705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analgesic activity of nabumetone versus naproxen in acute exacerbation of osteoarthritis. A short term study.
    Cazzola M; Montrone F; Azzolini V; Vaiani G; Caruso I
    Drugs; 1990; 40 Suppl 5():78-9. PubMed ID: 2081501
    [No Abstract]   [Full Text] [Related]  

  • 34. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance.
    Prieto A; De Barrio M; Martín E; Fernández-Bohórquez M; de Castro FJ; Ruiz FJ; Herrero T; Tornero P; Rubio M
    J Allergy Clin Immunol; 2007 Apr; 119(4):960-4. PubMed ID: 17292954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis.
    Bellamy N; Bensen WG; Beaulieu A; Siminovitch KA; Kraag GR; Lussier A; Ahmad S; Khanna VN; Davis P; Bell MJ
    J Rheumatol; 1995 May; 22(5):915-20. PubMed ID: 8587082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of nabumetone in patients with rheumatic diseases. Results of an outpatient study involving 8,865 patients.
    Stroehmann I; Giersch KH; Zeidler H; Münzel P
    Drugs; 1990; 40 Suppl 5():50-2. PubMed ID: 2081493
    [No Abstract]   [Full Text] [Related]  

  • 37. Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.
    Friedel HA; Todd PA
    Drugs; 1988 May; 35(5):504-24. PubMed ID: 3293969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.
    Bianchi Porro G; Montrone F; Petrillo M; Caruso I; Imbesi V
    Am J Gastroenterol; 1995 Sep; 90(9):1485-8. PubMed ID: 7661175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Worldwide safety experience with nabumetone.
    Bernhard GC
    J Rheumatol Suppl; 1992 Nov; 36():48-57. PubMed ID: 1474535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice.
    Carle WK; Wade AG; Kill DC; Poland M
    J Rheumatol Suppl; 1992 Nov; 36():58-62. PubMed ID: 1474536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.